5-硝基-呋喃-2-羧酸-(4-氯-苯胺) | 109844-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-硝基-呋喃-2-羧酸-(4-氯-苯胺)
• 英文名称: N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide
• CAS: 109844-92-0
• 化学式: C₁₁H₇ClN₂O₄
• mdl: MFCD00218079
• 分子量: 266.641
• InChiKey: JDBZJNUHQINERI-UHFFFAOYSA-N

物化性质

• 熔点：
  181 °C
• 沸点：
  328.2±37.0 °C(Predicted)
• 密度：
  1.524±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：微溶； DMSO：1mg/mL；乙醇：不溶； PBS (pH 7.2)：不溶

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-硝基-2-糠酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 5-硝基-呋喃-2-羧酸-(4-氯-苯胺)
  参考文献：
  名称：

  A Class of 5-Nitro-2-furancarboxylamides with Potent Trypanocidal Activity against Trypanosoma brucei in Vitro

  摘要：

  Recently, the World Health Organization approved the nifurtimox-eflornithine combination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases. In this study, we have synthesized a series of novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity, similar to 1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very low cytotoxicity against human He La cells. More importantly, the most potent analogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa. This implies that our novel, relatively easy to synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting a different, but still essential, biochemical process to those targeted by nifurtimox or its metabolites in the parasites. The significant increase in potency (smaller dose probably required) has the potential for greatly reducing unwanted side effects and also reducing the likelihood of drug resistance. Collectively, these findings have important implications for the future therapeutic treatment of African sleeping sickness.

  DOI：

  10.1021/jm301215e

文献信息

• Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent
  作者：Ricardo Gallardo-Macias、Pradeep Kumar、Mark Jaskowski、Todd Richmann、Riju Shrestha、Riccardo Russo、Eric Singleton、Matthew D. Zimmerman、Hsin Pin Ho、Véronique Dartois、Nancy Connell、David Alland、Joel S. Freundlich

  DOI：10.1016/j.bmcl.2018.12.053

  日期：2019.2

  The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019-0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40->120 μM) towards Vero cells. Significant

  硝基呋喃抗结核药物（N-benzyl-5-nitrofuran-2-carboxamide；JSF-3449）的优化活动促成了一系列类似物的设计、合成和生物学分析。这些化合物对结核分枝杆菌 H37Rv 菌株表现出有效的体外抗结核活性 (MIC = 0.019-0.20 μM)，对 Vero 细胞具有低体外细胞毒性 (CC50 = 40->120 μM)。通过引入 α, α-二甲基苄基部分实现了小鼠肝微粒体稳定性和小鼠药代动力学特征的显着改善。在这些化合物中，JSF-4088 因其体外抗结核效力 (MIC = 0.019 μM) 和 Vero 细胞毒性 (CC50 > 120 μM) 而备受瞩目。这些发现为这一有希望的抗结核小分子系列的持续进化提供了基本原理。
• PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS
  申请人：Djaballah Hakim

  公开号：US20100210649A1

  公开（公告）日：2010-08-19

  The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

  本发明涉及式(I)的吡啶二酮化合物和式(II)的呋喃化合物，以及式(I)和(II)化合物的制药组合物、包含这些化合物的试剂盒、合成方法，以及通过给予式(I)或(II)化合物的治疗有效量来治疗受体内增生性疾病的方法。这两类化合物是通过筛选小分子库的集合而确定的。
• Pyridazinones and furan-containing compounds
  申请人：Sloan-Kettering Institute For Cancer Research

  公开号：EP2518063A1

  公开（公告）日：2012-10-31

  The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

  本发明涉及式(I)哒嗪酮化合物和式(II)呋喃化合物、式(I)和(II)化合物的药物组合物、含有这些化合物的试剂盒、合成方法以及通过施用治疗有效量的式(I)或(II)化合物治疗受试者增殖性疾病的方法。这两类化合物都是通过筛选一系列小分子化合物库确定的。
• DIARYLAMIDE COMPOUND AND APPLICATION THEREOF
  申请人：Peking University

  公开号：EP3984534A1

  公开（公告）日：2022-04-20

  A use of a diarylamide compound having the structure as shown in formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug which acts as a urea transporter protein inhibitor, and a novel diarylamide compound. The diarylamide compound has urea transporter protein inhibitor effect, and can produce urea selective diuresis in the body without obvious toxicity.

  一种具有式（I）所示结构的二芳基酰胺化合物或其药学上可接受的盐在制备作为尿素转运蛋白抑制剂的药物中的用途，以及一种新型二芳基酰胺化合物。该二芳基酰胺化合物具有尿素转运蛋白抑制剂的作用，可在体内产生尿素选择性利尿作用，且无明显毒性。
• [EN] DIARYLAMIDE COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE DIARYLAMIDE ET SON APPLICATION<br/>[ZH] 二芳基酰胺类化合物及其应用
  申请人：UNIV BEIJING

  公开号：WO2020253802A1

  公开（公告）日：2020-12-24

  具有式(I)所示结构的二芳基酰胺类化合物、其药学上可接受的盐在制备作为尿素通道蛋白抑制剂的药物中的用途以及一类新型的二芳基酰胺类化合物，所述二芳基酰胺类化合物具有尿素通道蛋白抑制剂作用，能够在体内产生尿素选择性利尿并且没有明显的毒性作用。